JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
JPH06500574A
(ja)
|
1991-05-10 |
1994-01-20 |
ザ ソーク インスティテュート フォア バイオロジカル スタディーズ |
アクチビン/TGF―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
DK0592562T3
(da)
|
1991-06-25 |
1999-08-30 |
Genetics Inst |
BMP-9-præparater
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
CA2161807A1
(en)
|
1993-05-12 |
1994-11-24 |
Anthony J. Celeste |
Bmp-10 compositions
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
EP0726948B1
(en)
|
1993-10-14 |
2007-02-28 |
President And Fellows Of Harvard College |
Method of inducing and maintaining neuronal cells
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
JPH11502717A
(ja)
|
1995-04-11 |
1999-03-09 |
ザ ジェネラル ホスピタル コーポレーション |
逆ツーハイブリッドシステム
|
EP0771873A3
(en)
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
CZ130199A3
(cs)
|
1996-10-25 |
1999-07-14 |
G. D. Searle & Co. |
Cirkulárně permutovaní agonisté receptoru erythropoietinu
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
WO1999006563A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
WO1999006559A1
(en)
|
1997-08-01 |
1999-02-11 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (gdf) receptors
|
WO1999010364A1
(en)
|
1997-08-29 |
1999-03-04 |
Human Genome Sciences, Inc. |
Follistatin-3
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
EP1116792B1
(en)
|
1998-09-22 |
2007-01-24 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
DE60027135T2
(de)
|
1999-01-21 |
2007-01-11 |
Metamorphix, Inc. |
Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
|
CA2365449A1
(en)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibitor of the growth of androgen-independent tumor
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
JP2003513681A
(ja)
|
1999-11-12 |
2003-04-15 |
マキシゲン・ホールディングス・リミテッド |
インターフェロンガンマ・コンジュゲート
|
ATE319470T1
(de)
|
1999-12-15 |
2006-03-15 |
Res Dev Foundation |
Betaglycan als ein inhibin rezeptor und dessen verwendung
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
EP1303605A2
(en)
|
2000-07-19 |
2003-04-23 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
AU2002213251B2
(en)
|
2000-10-16 |
2007-06-14 |
Bristol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
DK1345959T3
(da)
|
2000-11-20 |
2011-09-05 |
Univ Illinois |
Membranscaffoldproteiner
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
EP1369130A1
(en)
|
2001-03-16 |
2003-12-10 |
Takeda Chemical Industries, Ltd. |
Process for producing sustained release preparation
|
JP4369662B2
(ja)
|
2001-04-26 |
2009-11-25 |
アビディア インコーポレイテッド |
単量体ドメインのコンビナトリアルライブラリー
|
DK2116259T3
(da)
|
2001-05-24 |
2012-05-21 |
Zymogenetics Inc |
TACI-immunoglobulinfusionsproteiner
|
WO2002094864A2
(en)
|
2001-05-25 |
2002-11-28 |
Genset S.A. |
Human cdnas and proteins and uses thereof
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
JP3888998B2
(ja)
|
2001-07-17 |
2007-03-07 |
帝人株式会社 |
PPARδ活性化作用を測定することを特徴とする物質の選択方法及び薬剤
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
US20030224397A1
(en)
|
2002-02-11 |
2003-12-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
MXPA04008150A
(es)
|
2002-02-21 |
2005-06-17 |
Wyeth Corp |
Gasp1: una proteina que contiene dominio de folistatina.
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
AU2003232485A1
(en)
|
2002-04-18 |
2003-10-27 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
BR0313729A
(pt)
|
2002-08-16 |
2005-06-21 |
Wyeth Corp |
Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
|
AU2003228509B2
(en)
|
2002-10-15 |
2008-06-26 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
SI1592416T1
(sl)
|
2003-02-07 |
2009-06-30 |
Prometic Biosciences Inc |
Maščobne kisline s srednjo dolžino verige, gliceridi in analogi kot stimulatorji eritropoeze
|
WO2004086953A2
(en)
|
2003-03-26 |
2004-10-14 |
The Board Of Trustees Of The University Of Arkansas |
Method for diagnosis and treatment of bone turnover
|
WO2010019832A2
(en)
|
2008-08-13 |
2010-02-18 |
Designer Molecules, Inc. |
Amide-extended crosslinking compounds and methods for use thereof
|
WO2005028517A2
(en)
|
2003-05-09 |
2005-03-31 |
The General Hospital Corporation |
SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
|
JP5110877B2
(ja)
|
2003-06-02 |
2012-12-26 |
ワイス・エルエルシー |
神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用
|
EP1636270B1
(en)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
US7611465B2
(en)
|
2003-07-15 |
2009-11-03 |
Board Of Regents, The University Of Texas System |
Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
DE10335211A1
(de)
|
2003-08-01 |
2005-02-17 |
Robert Bosch Gmbh |
Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
|
US20070135336A1
(en)
|
2003-09-15 |
2007-06-14 |
De Kretser David |
Follistatin isoforms and uses thereof
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
DE602005016773D1
(de)
|
2004-01-22 |
2009-11-05 |
Merck Patent Gmbh |
Antikrebs-antikörper mit reduzierter komplementfixierung
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
JP2007530055A
(ja)
|
2004-03-26 |
2007-11-01 |
アクセルロン ファーマ インコーポレーテッド |
Bmp−3プロペプチドおよび関連する方法
|
US7459527B2
(en)
|
2004-03-31 |
2008-12-02 |
Xencor, Inc. |
BMP-7 variants with improved properties
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
EP1771557B1
(en)
|
2004-06-24 |
2014-12-31 |
Acceleron Pharma Inc. |
GDF3 Propeptides and Related Methods
|
CA2574777C
(en)
|
2004-07-23 |
2015-09-01 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
US20060034831A1
(en)
|
2004-08-12 |
2006-02-16 |
Wyeth |
Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
WO2006052842A2
(en)
*
|
2004-11-09 |
2006-05-18 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosis of myelodysplastic syndromes (mds)
|
EP1824796A4
(en)
|
2004-11-16 |
2010-02-17 |
Avidia Res Inst |
PROTEIN SKELETONS AND USES THEREOF
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
ES2547866T3
(es)
|
2005-02-16 |
2015-10-09 |
The General Hospital Corporation |
Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
|
WO2006115274A1
(ja)
|
2005-04-26 |
2006-11-02 |
Ajinomoto Co., Inc. |
骨髄赤血球前駆細胞分化促進剤
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
DK1931697T3
(da)
|
2005-09-28 |
2010-11-08 |
Zymogenetics Inc |
IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
EP2329837B1
(en)
|
2005-11-23 |
2014-04-30 |
Acceleron Pharma Inc. |
Anti-activin A or B antibodies and use thereof for promoting bone growth
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
MX2008007324A
(es)
|
2005-12-06 |
2009-03-04 |
Amgen Inc |
Usos de antagonistas de miostatina.
|
CA2632936A1
(en)
|
2005-12-20 |
2007-06-28 |
Merck Frosst Canada Ltd. |
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
CA2634940A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
EP1976541B1
(en)
|
2006-01-20 |
2011-07-13 |
Beckman Coulter, Inc. |
Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
|
JP2009531280A
(ja)
|
2006-01-25 |
2009-09-03 |
ウェルスタット セラピューティクス コーポレイション |
代謝障害を処置するための化合物
|
NZ570100A
(en)
|
2006-02-28 |
2011-01-28 |
Wellstat Therapeutics Corp |
Compounds for the treatment of metabolic disorders
|
US8008074B2
(en)
|
2006-03-20 |
2011-08-30 |
The Uab Research Foundation |
Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
|
AU2007238705A1
(en)
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
US20080075692A1
(en)
|
2006-05-09 |
2008-03-27 |
Perrine Susan P |
Methods for treating blood disorders
|
BRPI0714882A2
(pt)
|
2006-07-21 |
2013-05-21 |
Lyne Lab |
composiÇço lÍquida de acetato de cÁlcio e uso de uma soluÇço aquosa que compreende entre cerca de 7% (p/v) e cerca de 21% (p/v) de acetato de cÁlcio
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
WO2008030367A2
(en)
|
2006-09-01 |
2008-03-13 |
The General Hospital Corporation |
Selective myostatin inhibitors
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
EP2103628A4
(en)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
|
ME02335B
(me)
|
2006-12-18 |
2013-04-30 |
Acceleron Pharma Inc |
Activin-actrii antagonisti i upotreba za liječenje anemije
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
AU2013221910B2
(en)
*
|
2006-12-18 |
2016-11-17 |
Acceleron Pharma Inc. |
Activin-ActRII antagonists and uses for increasing red blood cell levels
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
AU2008211007B2
(en)
|
2007-02-01 |
2013-09-19 |
Acceleron Pharma Inc. |
Activin-ActRIIa antagonists and uses for treating or preventing breast cancer
|
TW202104248A
(zh)
|
2007-02-02 |
2021-02-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
KR20190026047A
(ko)
|
2007-02-09 |
2019-03-12 |
악셀레론 파마 인코포레이티드 |
액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
WO2008151078A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
CA2685540C
(en)
|
2007-08-03 |
2018-10-16 |
Graham Michael Wynne |
Drug combinations for the treatment of duchenne muscular dystrophy
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
WO2009038745A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
WO2009070243A2
(en)
|
2007-11-21 |
2009-06-04 |
Amgen Inc. |
Wise binding agents and epitopes
|
WO2009114180A1
(en)
|
2008-03-13 |
2009-09-17 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
CA2725208A1
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
KR20190128002A
(ko)
*
|
2008-06-26 |
2019-11-13 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
CA2729098C
(en)
|
2008-06-26 |
2018-02-13 |
Acceleron Pharma Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
JP5922928B2
(ja)
|
2008-08-14 |
2016-05-24 |
アクセルロン ファーマ, インコーポレイテッド |
赤血球レベルを高めるためのgdfトラップの使用
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
WO2010089443A2
(es)
|
2009-02-05 |
2010-08-12 |
Digna Biotech,S.L. |
FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1
|
CA2758290C
(en)
|
2009-04-27 |
2018-04-10 |
Novartis Ag |
Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
|
CN104840944A
(zh)
|
2009-06-08 |
2015-08-19 |
阿塞勒隆制药公司 |
用于增加产热脂肪细胞的方法
|
CA2765108C
(en)
|
2009-06-12 |
2020-09-15 |
Acceleron Pharma Inc. |
Truncated actriib-fc fusion proteins
|
CN105412908B
(zh)
*
|
2009-08-13 |
2021-08-24 |
阿塞勒隆制药公司 |
Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
|
EP3919068A1
(en)
|
2009-09-09 |
2021-12-08 |
Acceleron Pharma Inc. |
Actriib antagonists and dosing and uses thereof for promoting ed blood cell formation
|
EP3818988A1
(en)
|
2009-11-03 |
2021-05-12 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
CA2781152A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
ES2741477T3
(es)
|
2011-10-17 |
2020-02-11 |
Acceleron Pharma Inc |
Composiciones para tratar la sobrecarga de hierro en talasemia
|
WO2014007198A1
(ja)
|
2012-07-02 |
2014-01-09 |
協和発酵キリン株式会社 |
抗bmp9抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
|
WO2014066487A2
(en)
|
2012-10-24 |
2014-05-01 |
Celgene Corporation |
Methods for treating anemia
|
IL267663B
(en)
*
|
2012-10-24 |
2022-09-01 |
Celgene Corp |
A biomarker for use in the treatment of anemia
|
CA3120678A1
(en)
|
2012-11-02 |
2014-05-08 |
Celgene Corporaiton |
Activin-actrii antagonists and uses for treating bone and other disorders
|
KR102520970B1
(ko)
|
2014-03-21 |
2023-04-12 |
악셀레론 파마 인코포레이티드 |
액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
|
CA2962197C
(en)
|
2014-04-18 |
2023-10-03 |
Ravindra Kumar |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
MA40008A
(fr)
|
2014-06-13 |
2021-05-05 |
Acceleron Pharma Inc |
Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
HRP20230504T1
(hr)
|
2014-12-03 |
2023-09-15 |
Celgene Corporation |
Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
AU2016261913B2
(en)
|
2015-05-13 |
2021-08-12 |
Acceleron Pharma Inc. |
Treatment of beta-thalassemia using ActRII ligand traps
|
CN108350057A
(zh)
|
2015-05-20 |
2018-07-31 |
细胞基因公司 |
使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
WO2017079591A2
(en)
|
2015-11-04 |
2017-05-11 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
WO2017091706A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
EP3928784A1
(en)
|
2016-07-15 |
2021-12-29 |
Acceleron Pharma Inc. |
Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
|
JP7264580B2
(ja)
|
2016-07-27 |
2023-04-25 |
アクセルロン ファーマ インコーポレイテッド |
骨髄線維症を処置するための方法および組成物
|
US11267865B2
(en)
|
2016-10-05 |
2022-03-08 |
Acceleron Pharma Inc. |
Variant ActRIIB proteins and uses thereof
|
DK3638243T3
(da)
|
2017-06-14 |
2024-10-28 |
Celgene Corp |
Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
|
CN112969471A
(zh)
|
2018-10-31 |
2021-06-15 |
细胞基因公司 |
使用激活素-actrii配体陷阱治疗具有环状铁粒幼细胞的受试者中由极低、低或中等风险的骨髓增生异常综合征引起的贫血
|